A Phase 1b Multicenter, Open-Label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) Either as Monotherapy or in Combination with Pomalidomide (POM) with or without Lowdose Dexamethasone (DEX) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

ID Number 16-1674

Principal Investigator(s)
Sundar Jagannath

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to test the safety of the combination of an experimental drug called durvalumab and pomalidomide at different dose levels, and to find out what effects, good or bad, the combination of these drugs has on you.

Contact Information
Lisa La
(212) 241-8615

Recruiting Patients: Yes